Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 312

1.

Control of the inflammatory response during pregnancy: potential role of VIP as a regulatory peptide.

Ramhorst R, Calo G, Paparini D, Vota D, Hauk V, Gallino L, Merech F, Grasso E, Leirós CP.

Ann N Y Acad Sci. 2018 May 8. doi: 10.1111/nyas.13632. [Epub ahead of print]

PMID:
29740848
2.

Synthesis and Structure-Activity Relationships of (-)-cis-N-Normetazocine-Based LP1 Derivatives.

Pasquinucci L, Parenti C, Amata E, Georgoussi Z, Pallaki P, Camarda V, Calò G, Arena E, Montenegro L, Turnaturi R.

Pharmaceuticals (Basel). 2018 May 5;11(2). pii: E40. doi: 10.3390/ph11020040.

3.

In vitro and in vivo activity of cyclopeptide Dmt-c[d-Lys-Phe-Asp]NH2, a mu opioid receptor agonist biased toward β-arrestin.

Gach-Janczak K, Piekielna-Ciesielska J, Adamska-Bartłomiejczyk A, Wtorek K, Ferrari F, Calo' G, Szymaszkiewicz A, Piasecka-Zelga J, Janecka A.

Peptides. 2018 Jul;105:51-57. doi: 10.1016/j.peptides.2018.04.014. Epub 2018 Apr 22.

PMID:
29684591
4.

In vitro and in vivo characterization of the bifunctional μ and δ opioid receptor ligand UFP-505.

Dietis N, Niwa H, Tose R, McDonald J, Ruggieri V, Filaferro M, Vitale G, Micheli L, Ghelardini C, Salvadori S, Calo G, Guerrini R, Rowbotham DJ, Lambert DG.

Br J Pharmacol. 2018 Jul;175(14):2881-2896. doi: 10.1111/bph.14199. Epub 2018 May 14.

PMID:
29524334
5.

Involvement of the N/OFQ-NOP system in rat morphine antinociceptive tolerance: Are astrocytes the crossroad?

Micheli L, Lucarini E, Corti F, Ciccocioppo R, Calò G, Rizzi A, Ghelardini C, Di Cesare Mannelli L.

Eur J Pharmacol. 2018 Mar 15;823:79-86. doi: 10.1016/j.ejphar.2018.01.039. Epub 2018 Jan 31.

PMID:
29378191
6.

Medico legal aspects on neuromonitoring in thyroid surgery: informed consent on malpractice claims.

Demontis R, Pittau MR, Maturo A, Petruzzo P, Calò G.

G Chir. 2017 May-Jun;38(3):149-154.

7.

Cyclopeptide Dmt-[D-Lys-p-CF3-Phe-Phe-Asp]NH2, a novel G protein-biased agonist of the mu opioid receptor.

Piekielna-Ciesielska J, Ferrari F, Calo' G, Janecka A.

Peptides. 2018 Mar;101:227-233. doi: 10.1016/j.peptides.2017.11.020. Epub 2017 Nov 28.

PMID:
29196181
8.

Central noradrenergic activity affects analgesic effect of Neuropeptide S.

Jinushi K, Kushikata T, Kudo T, Calo G, Guerrini R, Hirota K.

J Anesth. 2018 Feb;32(1):48-53. doi: 10.1007/s00540-017-2427-y. Epub 2017 Nov 11.

PMID:
29128909
9.

Peptide welding technology - A simple strategy for generating innovative ligands for G protein coupled receptors.

Calo' G, Rizzi A, Ruzza C, Ferrari F, Pacifico S, Gavioli EC, Salvadori S, Guerrini R.

Peptides. 2018 Jan;99:195-204. doi: 10.1016/j.peptides.2017.10.004. Epub 2017 Oct 13. Review.

PMID:
29031796
10.

Mitochondrial dysfunctions in bladder cancer: Exploring their role as disease markers and potential therapeutic targets.

Cormio A, Sanguedolce F, Musicco C, Pesce V, Calò G, Bufo P, Carrieri G, Cormio L.

Crit Rev Oncol Hematol. 2017 Sep;117:67-72. doi: 10.1016/j.critrevonc.2017.07.001. Epub 2017 Jul 11. Review.

PMID:
28807237
11.

In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403.

Ferrari F, Malfacini D, Journigan BV, Bird MF, Trapella C, Guerrini R, Lambert DG, Calo' G, Zaveri NT.

Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.333.

12.

Integrated Vivaldi plasmonic antenna for wireless on-chip optical communications.

Bellanca G, Calò G, Kaplan AE, Bassi P, Petruzzelli V.

Opt Express. 2017 Jul 10;25(14):16214-16227. doi: 10.1364/OE.25.016214.

PMID:
28789129
13.

Synthesis and activity of opioid peptidomimetics with β2- and β3-amino acids.

Gach-Janczak K, Piekielna-Ciesielska J, Adamska-Bartłomiejczyk A, Perlikowska R, Kruszyński R, Kluczyk A, Krzywik J, Sukiennik J, Cerlesi MC, Calo G, Wasilewski A, Zielińska M, Janecka A.

Peptides. 2017 Sep;95:116-123. doi: 10.1016/j.peptides.2017.07.015. Epub 2017 Aug 3.

PMID:
28782637
14.

Ancient signal for nitrogen status sensing in the green lineage: Functional evidence of CDPK repertoire in Ostreococcus tauri.

Caló G, Scheidegger D, Martínez-Noël GMA, Salerno GL.

Plant Physiol Biochem. 2017 Sep;118:377-384. doi: 10.1016/j.plaphy.2017.07.009. Epub 2017 Jul 8.

PMID:
28710945
15.

Activation of nociceptin/orphanin FQ receptors inhibits contextual fear memory reconsolidation.

Rekik K, Faria Da Silva R, Colom M, Pacifico S, Zaveri NT, Calo' G, Rampon C, Frances B, Mouledous L.

Neuropharmacology. 2017 Oct;125:39-49. doi: 10.1016/j.neuropharm.2017.07.006. Epub 2017 Jul 10.

PMID:
28705439
16.

Antinociceptive action of NOP and opioid receptor agonists in the mouse orofacial formalin test.

Rizzi A, Ruzza C, Bianco S, Trapella C, Calo' G.

Peptides. 2017 Aug;94:71-77. doi: 10.1016/j.peptides.2017.07.002. Epub 2017 Jul 8.

PMID:
28697954
17.

A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism.

Fantinati A, Bianco S, Guerrini R, Salvadori S, Pacifico S, Cerlesi MC, Calo G, Trapella C.

Sci Rep. 2017 May 25;7(1):2416. doi: 10.1038/s41598-017-02502-9.

18.

Human epidermal growth factor receptor 2 expression is more important than Bacillus Calmette Guerin treatment in predicting the outcome of T1G3 bladder cancer.

Cormio L, Sanguedolce F, Cormio A, Massenio P, Pedicillo MC, Cagiano S, Calò G, Pagliarulo V, Carrieri G, Bufo P.

Oncotarget. 2017 Apr 11;8(15):25433-25441. doi: 10.18632/oncotarget.15989.

19.

A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials.

Eleuteri C, Olla S, Veroni C, Umeton R, Mechelli R, Romano S, Buscarinu MC, Ferrari F, Calò G, Ristori G, Salvetti M, Agresti C.

Sci Rep. 2017 Apr 7;7:45780. doi: 10.1038/srep45780.

20.

Structure- and conformation-activity studies of nociceptin/orphanin FQ receptor dimeric ligands.

Pacifico S, Carotenuto A, Brancaccio D, Novellino E, Marzola E, Ferrari F, Cerlesi MC, Trapella C, Preti D, Salvadori S, Calò G, Guerrini R.

Sci Rep. 2017 Apr 6;7:45817. doi: 10.1038/srep45817.

21.

Cyclic mu-opioid receptor ligands containing multiple N-methylated amino acid residues.

Adamska-Bartłomiejczyk A, Janecka A, Szabó MR, Cerlesi MC, Calo G, Kluczyk A, Tömböly C, Borics A.

Bioorg Med Chem Lett. 2017 Apr 15;27(8):1644-1648. doi: 10.1016/j.bmcl.2017.03.016. Epub 2017 Mar 7.

PMID:
28318942
22.

Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist.

Rizzi A, Cerlesi MC, Ruzza C, Malfacini D, Ferrari F, Bianco S, Costa T, Guerrini R, Trapella C, Calo' G.

Pharmacol Res Perspect. 2016 Aug 2;4(4):e00247. doi: 10.1002/prp2.247. eCollection 2016 Aug.

23.

Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome?

Piscaglia AC, Laterza L, Cesario V, Gerardi V, Landi R, Lopetuso LR, Calò G, Fabbretti G, Brisigotti M, Stefanelli ML, Gasbarrini A.

World J Gastroenterol. 2016 Dec 14;22(46):10198-10209. doi: 10.3748/wjg.v22.i46.10198.

24.

Trophoblast cells inhibit neutrophil extracellular trap formation and enhance apoptosis through vasoactive intestinal peptide-mediated pathways.

Calo G, Sabbione F, Vota D, Paparini D, Ramhorst R, Trevani A, Pérez Leirós C.

Hum Reprod. 2017 Jan;32(1):55-64. Epub 2016 Dec 7.

PMID:
27932441
25.

Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt1]N/OFQ(1-13).

Cerlesi MC, Ding H, Bird MF, Kiguchi N, Ferrari F, Malfacini D, Rizzi A, Ruzza C, Lambert DG, Ko MC, Calo G, Guerrini R.

Eur J Pharmacol. 2017 Jan 5;794:115-126. doi: 10.1016/j.ejphar.2016.11.026. Epub 2016 Nov 19.

26.

Neuropeptide S receptor ligands: a patent review (2005-2016).

Ruzza C, Calò G, Di Maro S, Pacifico S, Trapella C, Salvadori S, Preti D, Guerrini R.

Expert Opin Ther Pat. 2017 Mar;27(3):347-362. doi: 10.1080/13543776.2017.1254195. Epub 2016 Nov 9. Review.

PMID:
27788040
27.

In vitro functional characterization of novel nociceptin/orphanin FQ receptor agonists in recombinant and native preparations.

Ferrari F, Cerlesi MC, Malfacini D, Asth L, Gavioli EC, Journigan BV, Kamakolanu UG, Meyer ME, Yasuda D, Polgar WE, Rizzi A, Guerrini R, Ruzza C, Zaveri NT, Calo G.

Eur J Pharmacol. 2016 Dec 15;793:1-13. doi: 10.1016/j.ejphar.2016.10.025. Epub 2016 Oct 22.

28.

Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction.

Kallupi M, Scuppa G, de Guglielmo G, Calò G, Weiss F, Statnick MA, Rorick-Kehn LM, Ciccocioppo R.

Neuropsychopharmacology. 2017 Feb;42(3):695-706. doi: 10.1038/npp.2016.171. Epub 2016 Aug 26.

29.

Correction for "Synthesis of Mixed Opioid Affinity Cyclic Endomorphin-2 Analogues with Fluorinated Phenylalanines".

Piekielna J, Perlikowska R, do-Rego JC, do-Rego JL, Cerlesi MC, Calo G, Kluczyk A, Łapiński K, Tömböly C, Janecka A.

ACS Med Chem Lett. 2016 May 9;7(6):652. doi: 10.1021/acsmedchemlett.6b00162. eCollection 2016 Jun 9.

30.

Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo).

Bird MF, Cerlesi MC, Brown M, Malfacini D, Vezzi V, Molinari P, Micheli L, Di Cesare Mannelli L, Ghelardini C, Guerrini R, Calò G, Lambert DG.

PLoS One. 2016 Jun 7;11(6):e0156897. doi: 10.1371/journal.pone.0156897. eCollection 2016.

31.

Antidepressant activity of nociceptin/orphanin FQ receptor antagonists in the mouse learned helplessness.

Holanda VA, Medeiros IU, Asth L, Guerrini R, Calo' G, Gavioli EC.

Psychopharmacology (Berl). 2016 Jul;233(13):2525-32. doi: 10.1007/s00213-016-4310-1. Epub 2016 Apr 30.

PMID:
27129865
32.

Redoubling the ring size of an endomorphin-2 analog transforms a centrally acting mu-opioid receptor agonist into a pure peripheral analgesic.

Piekielna J, De Marco R, Gentilucci L, Cerlesi MC, Calo' G, Tömböly C, Artali R, Janecka A.

Biopolymers. 2016 May;106(3):309-17. doi: 10.1002/bip.22846.

PMID:
27038094
33.

Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Toll L, Bruchas MR, Calo' G, Cox BM, Zaveri NT.

Pharmacol Rev. 2016 Apr;68(2):419-57. doi: 10.1124/pr.114.009209. Epub 2016 Mar 8. Review.

34.

Synthesis, biological evaluation and structural analysis of novel peripherally active morphiceptin analogs.

Adamska A, Kluczyk A, Cerlesi MC, Calo G, Janecka A, Borics A.

Bioorg Med Chem. 2016 Apr 1;24(7):1582-8. doi: 10.1016/j.bmc.2016.02.034. Epub 2016 Feb 26.

PMID:
26944625
35.

Decoding the chemokine network that links leukocytes with decidual cells and the trophoblast during early implantation.

Ramhorst R, Grasso E, Paparini D, Hauk V, Gallino L, Calo G, Vota D, Pérez Leirós C.

Cell Adh Migr. 2016 Mar 3;10(1-2):197-207. doi: 10.1080/19336918.2015.1135285. Epub 2016 Feb 18. Review.

36.

Differentiated thyroid cancer: feasibility of loboisthmectomy in an endemic region.

Calò G, Erdas E, Medas F, Gordini L, Longheu A, Pisano G, Nicolosi A.

G Chir. 2015 Nov-Dec;36(6):257-62.

37.

Beta-arrestin 2 rather than G protein efficacy determines the anxiolytic-versus antidepressant-like effects of nociceptin/orphanin FQ receptor ligands.

Asth L, Ruzza C, Malfacini D, Medeiros I, Guerrini R, Zaveri NT, Gavioli EC, Calo' G.

Neuropharmacology. 2016 Jun;105:434-442. doi: 10.1016/j.neuropharm.2016.02.003. Epub 2016 Feb 8.

38.

Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.

Arcuri L, Viaro R, Bido S, Longo F, Calcagno M, Fernagut PO, Zaveri NT, Calò G, Bezard E, Morari M.

Neurobiol Dis. 2016 May;89:55-64. doi: 10.1016/j.nbd.2016.01.016. Epub 2016 Jan 22.

39.

Synthesis of mixed MOR/KOR efficacy cyclic opioid peptide analogs with antinociceptive activity after systemic administration.

Perlikowska R, Piekielna J, Gentilucci L, De Marco R, Cerlesi MC, Calo G, Artali R, Tömböly C, Kluczyk A, Janecka A.

Eur J Med Chem. 2016 Feb 15;109:276-86. doi: 10.1016/j.ejmech.2015.12.012. Epub 2015 Dec 12.

PMID:
26785295
40.

Nociceptin/orphanin FQ (N/OFQ) modulates immunopathology and airway hyperresponsiveness representing a novel target for the treatment of asthma.

Singh SR, Sullo N, Matteis M, Spaziano G, McDonald J, Saunders R, Woodman L, Urbanek K, De Angelis A, De Palma R, Berair R, Pancholi M, Mistry V, Rossi F, Guerrini R, Calò G, D'Agostino B, Brightling CE, Lambert DG.

Br J Pharmacol. 2016 Apr;173(8):1286-301. doi: 10.1111/bph.13416. Epub 2016 Mar 6.

41.

VIP treatment prevents embryo resorption by modulating efferocytosis and activation profile of maternal macrophages in the CBAxDBA resorption prone model.

Gallino L, Calo G, Hauk V, Fraccaroli L, Grasso E, Vermeulen M, Leirós CP, Ramhorst R.

Sci Rep. 2016 Jan 6;6:18633. doi: 10.1038/srep18633.

42.

The Importance of Ligand-Receptor Conformational Pairs in Stabilization: Spotlight on the N/OFQ G Protein-Coupled Receptor.

Miller RL, Thompson AA, Trapella C, Guerrini R, Malfacini D, Patel N, Han GW, Cherezov V, Caló G, Katritch V, Stevens RC.

Structure. 2015 Dec 1;23(12):2291-2299. doi: 10.1016/j.str.2015.07.024. Epub 2015 Oct 29.

43.

Trophoblast cells primed with vasoactive intestinal peptide enhance monocyte migration and apoptotic cell clearance through αvβ3 integrin portal formation in a model of maternal-placental interaction.

Paparini D, Grasso E, Calo G, Vota D, Hauk V, Ramhorst R, Leirós CP.

Mol Hum Reprod. 2015 Dec;21(12):930-41. doi: 10.1093/molehr/gav059. Epub 2015 Oct 26.

PMID:
26502804
44.

Intrathecal administration of nociceptin/orphanin FQ receptor agonists in rats: A strategy to relieve chemotherapy-induced neuropathic hypersensitivity.

Micheli L, Di Cesare Mannelli L, Rizzi A, Guerrini R, Trapella C, Calò G, Ghelardini C.

Eur J Pharmacol. 2015 Nov 5;766:155-62. doi: 10.1016/j.ejphar.2015.10.005. Epub 2015 Oct 9.

PMID:
26450087
45.

Pharmacological Profile of Nociceptin/Orphanin FQ Receptors Interacting with G-Proteins and β-Arrestins 2.

Malfacini D, Ambrosio C, Gro' MC, Sbraccia M, Trapella C, Guerrini R, Bonora M, Pinton P, Costa T, Calo' G.

PLoS One. 2015 Aug 6;10(8):e0132865. doi: 10.1371/journal.pone.0132865. eCollection 2015.

46.

Blockade of nociceptin/orphanin FQ receptor signaling reverses LPS-induced depressive-like behavior in mice.

Medeiros IU, Ruzza C, Asth L, Guerrini R, Romão PR, Gavioli EC, Calo G.

Peptides. 2015 Oct;72:95-103. doi: 10.1016/j.peptides.2015.05.006. Epub 2015 May 28.

47.

Comparison of three patterns of feed supplementation with live Saccharomyces cerevisiae yeast on postweaning diarrhea, health status, and blood metabolic profile of susceptible weaning pigs orally challenged with Escherichia coli F4ac.

Trevisi P, Colombo M, Priori D, Fontanesi L, Galimberti G, Calò G, Motta V, Latorre R, Fanelli F, Mezzullo M, Pagotto U, Gherpelli Y, D'Inca R, Bosi P.

J Anim Sci. 2015 May;93(5):2225-33. doi: 10.2527/jas.2014-8539.

PMID:
26020319
48.

Synthesis of mixed opioid affinity cyclic endomorphin-2 analogues with fluorinated phenylalanines.

Piekielna J, Perlikowska R, do-Rego JC, do-Rego JL, Cerlesi MC, Calo G, Kluczyk A, Łapiński K, Tömböly C, Janecka A.

ACS Med Chem Lett. 2015 Apr 3;6(5):579-83. doi: 10.1021/acsmedchemlett.5b00056. eCollection 2015 May 14. Erratum in: ACS Med Chem Lett. 2016 Jun 9;7(6):652.

49.

Ring size in cyclic endomorphin-2 analogs modulates receptor binding affinity and selectivity.

Piekielna J, Kluczyk A, Gentilucci L, Cerlesi MC, Calo' G, Tomböly C, Łapiński K, Janecki T, Janecka A.

Org Biomol Chem. 2015 Jun 7;13(21):6039-46. doi: 10.1039/c5ob00565e.

PMID:
25948019
50.

In vitro and in vivo pharmacological characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant.

Ruzza C, Rizzi A, Malfacini D, Molinari S, Giuliano C, Lovati E, Pietra C, Calo' G.

Peptides. 2015 Jul;69:26-32. doi: 10.1016/j.peptides.2015.03.021. Epub 2015 Apr 3.

PMID:
25843024

Supplemental Content

Support Center